Sudeep Pharma Ltd Q3 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 7 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹10.8K Cr
The company expects to sustain growth similar to the strong performance seen over the last couple of years, aiming for continued 35%-40% growth. Management refrains from giving specific revenue growth guidance but aims to sustain the strong growth momentum achieved in recent years, around 35%-40%, with a stable margin profile.
From Sudeep Pharma Ltd's Q3 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹1,112
Market Cap
₹10.8K Cr
P/E Ratio
59.3
How does Sudeep Pharma Ltd rank in Pharmaceuticals & Biotechnology?
Compare Sudeep Pharma Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Sudeep Pharma Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹182 Cr, net profit ₹49 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company expects to sustain growth similar to the strong performance seen over the last couple of years, aiming for continued 35%-40% growth.
- →Specialty ingredients, currently at ~40% capacity utilization, are anticipated to be a key growth driver over the next two years with increasing customer approvals.
- →The pharma, food, and nutrition vertical, now with greenfield capacity coming online, is expected to ramp up utilization to 30%-40% by FY '28.
- →Battery chemicals segment will start contributing revenue from FY '28, with phase-wise capacity scaling from 25,000 tons to potentially 100,000 tons depending on offtake agreements.
- →Capacity expansions in core and specialty products are aligned with anticipated customer demand and market approvals, supporting stable margin profiles.
- →Growth will be driven by expanded geographic presence, including North America, Europe, and Asia-Pacific, with increasing export contribution.
📈 Profitability & Margins
- →Management refrains from giving specific revenue growth guidance but aims to sustain the strong growth momentum achieved in recent years, around 35%-40%, with a stable margin profile.
- →Specialty ingredients, now 40% of revenue, expected to remain a key growth driver over the next two years with capacity utilization planned to ramp up from 40% towards 70%-80%.
- →Pharma, food and nutrition verticals to grow steadily, with new greenfield capacities coming online driving incremental growth.
- →Battery chemicals segment to start contributing revenue from FY '28, with initial capacity ramp-up starting early 2027; anticipated strong asset turns (~3x) and potential for higher-than-industry margins in this segment.
- →EBITDA margins expected to be stable around historical levels (~35%-37%).
- →Overall, growth is expected to be sustained with steady operating earnings and profits expansion, supported by new product launches, geographic expansion, and additional capacities.
🏗️ Capital Expenditure Plans
- →Core Business (Pharma, Food Nutrition):
- → - Greenfield facility at Nandesari with 51,200 MT capacity, commissioning by March 2026 (Q4 FY '26).
- → - Majority of capex for this project already spent; residual INR 10-15 crores expected by April 2026.
- → - No significant further capex planned; existing capacity sufficient for growth.
- →Specialty Ingredients:
- → - Currently 35%-40% utilization; no major capex planned.
- → - Growth driven by approvals and expansion in this segment.
- →Battery Materials Project:
- → - Total capex approx. INR 550-600 crores for 100,000 tons capacity.
- → - Phase 1 (25,000 tons) capex approx. INR 300 crores, including land.
- → - Project completion expected in 18 months (early 2027 for phase 1).
- → - Primarily funded through internal accruals; minimal expected interest impact.
- → - Phase 1 commissioning early 2027; revenue contribution from FY 28 onwards.
💰 Fundraising & Capital Structure
- →No significant interest impact expected in the near term from the battery materials project as it is mainly financed through internal accruals.
- →Debt levels will be monitored and managed as the battery project progresses.
- →Major funding for the battery materials project (INR 550-600 crores capex) is planned via internal accruals rather than external debt.
- →No mention of immediate or planned equity fundraising.
- →Capex for other verticals (specialty ingredients, pharma food nutrition) mostly completed; no major capex planned that would require new fundraising.
- →Overall, current focus is on internal accrual financing with careful debt management, no significant new fundraising announced.
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Sudeep Pharma Ltd Q3 FY26 results?
The company expects to sustain growth similar to the strong performance seen over the last couple of years, aiming for continued 35%-40% growth. Management refrains from giving specific revenue growth guidance but aims to sustain the strong growth momentum achieved in recent years, around 35%-40%, with a stable margin profile.
What is Sudeep Pharma Ltd share price analysis?
Sudeep Pharma Ltd currently shows a neutral. The stock trades at a P/E of 59.3 with a market cap of ₹10,831 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sudeep Pharma Ltd planning capital expenditure?
Core Business (Pharma, Food Nutrition): - Greenfield facility at Nandesari with 51,200 MT capacity, commissioning by March 2026 (Q4 FY '26). - Majority of capex for this project already spent; residual INR 10-15 crores expected by April 2026. - No significant further capex planned; existing capacity sufficient for growth. - Specialty Ingredients: - Currently 35%-40% utilization; no major capex planned. - Growth driven by approvals and expansion in this segment. - Battery Materials Project: - Total capex approx.
Keep Sudeep Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.